Lockheed Martin-backed Tempo Automation sealed its reverse merger while Strand Therapeutics upped a round featuring Eli Lilly and Beigene to $97m.
Public markets
Tempo Automation, a US-based industrial automation software provider that counts aerospace manufacturer Lockheed Martin as an investor, completed its reverse merger with special purpose acquisition company Ace Convergence Acquisition Corp and is now listed on the Nasdaq market. It agreed the $919m deal in October 2021.